A Phase I, Open-Label, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of a Single Oral Dose of RVX000222 in Subjects with Severe Renal Impairment.
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2017
At a glance
- Drugs Apabetalone (Primary)
- Indications Acute coronary syndromes; Alzheimer's disease; Low HDL cholesterol; Prediabetic-state
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Resverlogix Corporation
- 23 Jan 2017 Results published in a Resverlogix Corporation media release.
- 17 Nov 2016 According to a Resverlogix Corporation media release, status changed from active, no longer recruiting to completed.
- 17 Nov 2016 According to a resverlogix Corp. media release, the company announced successful results from this trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History